Mouse-Dog-Human Preclinical Cancer Model for Osteosarcoma Proposed

Share this content:
Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.
Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.
The following article features coverage from the Connective Tissue Oncology Society (CTOS) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Drug screens in both canine and human osteosarcoma patient-derived xenograft mouse model and cell lines can identify targeted agents in osteosarcoma — and according to study results from researchers in veterinary medicine, the cancer-killing ability across a screen of 119 cancer drugs in both dog and human cell lines “demonstrated that canine and human osteosarcoma cell lines are indistinguishable.” These findings were presented at the Connective Tissue Oncology Society (CTOS) 2018 Annual Meeting in Rome, Italy.1

The investigators sought to validate their so-called mouse-dog-human (MDH) personalized medicine pipeline in response to the high prevalence of osteosarcoma in dogs. More than 50,000 new diagnoses of osteosarcoma per year occur in dogs, compared with only 1000 new cases per year in humans. Plus, they noted that similarities between the species have already been well established.

Continue Reading Below

To test just how closely these species are linked, they created 5 human and 4 canine PDX cell lines in which the 119 US Food and Drug Administration-approved drugs were tested. They also performed an expanded drug screen using the National Institute of Health's Bioactive 2100 compound assay. Based on the results of the screens, bortezomib, verdinexor, and alvespimycin were selected for validation in vivo.

The drugs that were used to kill canine and human cancer cell lines performed similarly across both species, and they determined that proteasome inhibitors were “top drug candidates for all osteosarcoma cell lines alongside standard of care therapies.” Following an expanded drug screen, they concluded that verdinexor inhibited tumor growth (P < .05) in both human and canine PDX mouse models compared with controls (ie, cells treated with DMSO). Bortezomib reduced tumor growth in canine PDX models but not human PDX models, although both cell lines were sensitive to the drug in vitro. Alvespimycin was not efficacious in cell lines of either species, “highlighting the need for in vivo validation following in vitro drug screens.”

The researchers ultimately concluded that “on a population level, this cross-species approach could make significant contributions to discovering novel standard-of-care therapies.”

Read more of Cancer Therapy Advisor's coverage of the CTOS 2018 meeting by visiting the conference page.

Reference

  1. Rao S, Altune E, Glover W, et al. Shifting the paradigm in preclinical cancer modeling: a mouse-dog-human personalized medicine pipeline to identify novel therapeutics for osteosarcoma. Presented at: CTOS 2018 Annual Meeting; Rome, Italy: November 14-17. Poster 015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs